GNPX

Genprex, Inc.

NasdaqCMUSDEQUITY DELAYED

3.92

▼ 0.03 (0.76%)

MARKET · —

Price

Open

3.90

Prev close

3.95

Day high

4.29

Day low

3.87

Volume

94.48K

Market cap

—

P/E (TTM)

—

52W range

3.83 – 1,210.00

Trailing performance

Price return · vs SPY

Returnvs SPY

-8.56% -7.2%

-47.26% -51.0%

-77.97% -81.1%

-89.91% -101.0%

YTD

-89.74% -102.0%

-97.80% -117.8%

-99.98% -174.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

4.29

-8.61% from price

SMA 20

5.01

-21.12% from price

SMA 50

8.52

-53.63% from price

SMA 100

15.05

-73.96% from price

SMA 200

35.61

-88.91% from price

EMA 12

4.50

-12.93% from price

EMA 26

5.93

-33.86% from price

EMA 50

9.02

-56.52% from price

RSI (14)

28.1

Oversold

MACD (12,26,9)

-1.42

Hist 0.19

ATR (14)

0.56

14.14% of price

Realised vol 30D

145.0%

Annualised

Bollinger upper

7.49

20, 2σ

Bollinger lower

2.52

20, 2σ

50 / 200 cross

Death

8.52 vs 35.61

Trend bias

Below 200

-88.91%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.90

More volatile than market

Correlation to SPY

0.09

Largely independent

Realised vol 30D

145.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-99.6%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.56

14.14% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.92

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

GNPX · links out to the publisher

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy PR Newswire · 4d ago Genprex Shares Rise After Collaboration With Roche Diagnostics InvestorsHub · 19d ago Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies PR Newswire · 19d ago Genprex’s Reqorsa combo secures Canadian patent for lung cancer Pharmaceutical Technology · 60d ago Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer PR Newswire · 61d ago Genprex to Participate at BIO International Convention 2026 PR Newswire · 66d ago Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting PR Newswire · 88d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.